arrow
Z

Zhongfang Wang

Guangzhou Laboratory
H指数:27
被引数:3,025

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Safety and Immunogenicity of a PD-1-Enhanced HIV-1 Therapeutic DNA Vaccine: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I Clinical Trial in People With HIV-1 on Antiretroviral Therapy

PD-1增强型HIV-1治疗性DNA疫苗的安全性与免疫原性:一项在抗逆转录病毒治疗中的HIV-1感染者中进行的随机、双盲、安慰剂对照、剂量递增的I期临床试验

2026-07-140
PRE
Comprehensive profiling of smoke-induced T cells in mice implicates clonal γδT17 cells as a hallmark of COPD

吸烟诱导的小鼠T细胞的综合分析表明克隆 γδT17细胞是COPD的标志

2025-12-080
OAAI
Developing an eVLP mRNA vaccine for respiratory syncytial virus with enhanced pre-fusion targeting humoral responses

开发一种针对呼吸道合胞病毒、增强前融合靶向体液反应的eVLP mRNA疫苗

2025-09-010
PRE
Adenovirus Nanoparticles Displaying RBD Induce a Protective Immune Response Against BA.5 in Mice

显示RBD的腺病毒纳米颗粒在小鼠中诱导针对BA.5的保护性免疫反应

2025-08-060
OA
The spike 486 site is a key immune evasion point and a determinant of the immunogenicity of the RBD-dimer mRNA vaccine against SARS-CoV-2 variants

刺突蛋白486位点是一个关键的免疫逃逸位点,也是决定针对SARS-CoV-2变异株的RBD二聚体mRNA疫苗免疫原性的决定因素。

2025-07-020
PRE
Efficacy, immunogenicity, and safety of heterologous boosting with a novel chimera Chinese mRNA (RQ3013) SARS-CoV-2 vaccine: A randomized, double-blind, active-controlled trial

一种新型嵌合体中国mRNA (RQ3013) SARS-CoV-2疫苗的有效性、免疫原性和安全性: 一项随机、双盲、主动对照试验

2025-05-160
OA
Individuals carrying the HLA-B*15 allele exhibit favorable responses to COVID-19 vaccines but are more susceptible to Omicron BA.5.2 and XBB.1.16 infection

携带hla-b * 15等位基因的个体对新型冠状病毒肺炎疫苗表现出良好的反应,但对Omicron BA.5.2和XBB.1.16感染更敏感

2024-08-270
OAAI